A61K 2239/52
Intestine
A61K2239/52 (Intestine) appears on 5 US grants and 23 published applications in this corpus.
Search patents in A61K- Granted patents
- 5
- Published applications
- 23
- Assignees
- 21
- Inventors
- 71
- Latest grant
- 26 Oct 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 4 |
| 2021 | 2 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 2 |
| 2026 | 0 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Tumor infiltrating lymphocytes and methods of therapy26 Oct 2021US 11,154,574 B2Intima Bioscience, Inc.
- Tumor infiltrating lymphocytes and methods of therapy9 Feb 2021US 10,912,797 B2Intima Bioscience, Inc.
- Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis10 Jan 2017US 9,540,439 B2St. Jude Children?S Research Hospital
- Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells22 Dec 2015US 9,216,200 B2Anthrogenesis Corporation
- Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells11 Sep 2012US 8,263,065 B2Anthrogenesis Corporation
- Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof6 Aug 2026US 2026/0224700 A1Yale University
- Anti-5t4 antibody-natural killer cell conjugate and use thereof23 Jul 2026US 2026/0207746 A1Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Compositions and methods for generating neo-antigen reactive tumor infiltrating lymphocytes4 Jun 2026US 2026/0151484 A1Turnstone Biologics Corp.
- Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)19 Feb 2026US 2026/0048084 A1Artiva Biotherapeutics, Inc.
- Enhanced cd8+ t cells for cancer immunotherapy31 Jul 2025US 2025/0242022 A1Humanitas Mirasole S.P.A.
Most cited
By later US patents
- Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells24US 8,263,065 B2Anthrogenesis Corporation · 2012
- Tumor infiltrating lymphocytes and methods of therapy9US 10,912,797 B2Intima Bioscience, Inc. · 2021
- Tumor infiltrating lymphocytes and methods of therapy8US 11,154,574 B2Intima Bioscience, Inc. · 2021
- Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells3US 9,216,200 B2Anthrogenesis Corporation · 2015
- Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis1US 9,540,439 B2St. Jude Children?S Research Hospital · 2017